Could a common heart drug protect HIV patients from heart failure?
NCT ID NCT04153136
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether a drug called sacubitril-valsartan (Entresto) can improve early signs of heart failure in people with HIV. The 39 participants had well-controlled HIV but showed subtle heart changes on scans. The goal was to see if the drug could reduce inflammation and improve heart function, potentially preventing full-blown heart failure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sacubitril-Valsartan (Entresto)
What this could lead to
If successful, this could point toward a way to prevent or slow heart failure in people with HIV.
What could go wrong
This is a small, early-phase study with only 39 participants. It may not show clear benefits, and the drug can cause side effects like low blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV/AIDS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States